76P Real-world study of ESR1 mutation testing by liquid biopsy using digital PCR or NGS to guide elacestrant use in metastatic breast cancer patients
Year: 2025
Type: article
Abstract: The EMERALD trial (NCT03778931) showed improved PFS with elacestrant vs standard of care (SOC) endocrine therapy (ET) in patients with ER+/HER2− mBC and tumors harboring ESR1-mut after prior ET+CDK4/6i; HR=0.55; 95% CI, 0.39-0.77; P=0.0005 (Bidard 2022), leading to its approval by FDA, EMA, MHRA and other regulatory agencies. An Early Access Program (EAP) was initiated in Europe to enable patient access to elacestrant before reimbursement. The availability of elacestrant emphasizes the need for real-time mutation detection upon progression to guide treatments.
Source: ESMO Open
Authors: F.G.T. Rojo, V. Guarneri, A. Boscolo Bragadin, S. Indraccolo, E. Guerini Rocco, N. Fusco, S. Zazo, I. Prieto-Potin, R. Adorisio, F. Pepe, J. Herzog, M. Orellana, U. Malapelle
Institutions: Hospital Universitario Fundación Jiménez Díaz, Centro de Investigación Biomédica en Red de Cáncer, GEICAM – Spanish Breast Cancer Group, University of Padua, Istituto Oncologico Veneto, European Institute of Oncology, Federico II University Hospital, Menarini Group (Italy), University of Naples Federico II
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
Funders: AstraZeneca, GlaxoSmithKline
OpenAlex ID: W4410463539
